Skip to main content
EBS
NYSE Life Sciences

Emergent BioSolutions Secures $52.7M Government Contract for Smallpox Vaccine

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$8.405
Mkt Cap
$433.667M
52W Low
$5.615
52W High
$14.06
52W Position info
50% above low
Off High info
40% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

EBS sits 50% above its 52-week low of $5.615 on light trading volume (0.2× avg).

Summary

Emergent BioSolutions announced a $52.7 million contract modification from the U.S. government to supply its ACAM2000® vaccine, ensuring continued revenue from its biodefense portfolio.


Key Events · M&A and Partnerships · EBS

  • $52.7 Million Contract Awarded

    Emergent BioSolutions received a contract modification valued at $52.7 million from the U.S. Department of Health and Human Services (ASPR).

  • ACAM2000® Vaccine Supply

    The contract is for the supply of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live), ancillaries, and diluent replacement lots to the U.S. government.

  • Continuation of Existing Agreement

    This modification exercises Option Year 7 under Emergent's existing 10-year contract with ASPR, with deliveries expected to begin in June 2026.


Analysis · EBS · Life Sciences

This 8-K confirms a significant contract modification for Emergent BioSolutions, securing $52.7 million from the U.S. government to supply its ACAM2000® smallpox and mpox vaccine. This contract, an exercise of Option Year 7 under an existing agreement, represents a substantial revenue stream for the company, reinforcing its role in biodefense preparedness and providing financial stability.

How filings like this one have moved

In the 30 days to Oct 31, 2026, 40% of the 987 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EBS was trading at $8.41 on NYSE in the Life Sciences sector, with a market capitalization of approximately $433.7M. The 52-week trading range was $5.62 to $14.06. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EBS - Latest Insights

EBS
Oct 16, 2026, 7:52 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.11
Real-time Price: $6.81 info
Change: -$0.295 (-4%) info
Market Cap: $349.171M info
EBS
Oct 16, 2026, 7:48 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.15
Real-time Price: $6.81 info
Change: -$0.340 (-5%) info
Market Cap: $349.171M info
EBS
Sep 14, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.38
Real-time Price: $6.81 info
Change: +$0.430 (+7%) info
Market Cap: $349.171M info
EBS
Sep 01, 2026, 7:55 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $6.12
Real-time Price: $6.81 info
Change: +$0.690 (+11%) info
Market Cap: $349.171M info
EBS
Aug 05, 2026, 5:47 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $6.19
Real-time Price: $6.81 info
Change: +$0.620 (+10%) info
Market Cap: $349.171M info